Summary

U.S. DNA Synthesis Market Summary

The U.S. DNA synthesis market size was estimated at USD 1.25 billion in 2024 and is projected to reach USD 4.62 billion by 2033, expanding at a CAGR of 15.93% from 2025 to 2033. This high growth is driven by increasing demand in synthetic biology, personalized medicine, and biotechnology research. Advancements in gene editing technologies and declining costs of U.S. DNA synthesis are further accelerating market expansion. The U.S. remains a key player in global genomic innovation, supported by strong investment in R&D and a well-established biotech infrastructure.

U.S. DNA Synthesis Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. DNA synthesis market on the basis of service type, application, and end use.

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)
• Oligonucleotide Synthesis
o By Type
o Standard Oligonucleotide Synthesis
o Custom Oligonucleotide Synthesis
o By Length
o Less than 50 nt
o 51-100 nt
o 101-150 nt
o More than 150 nt
• Gene Synthesis
o By Type
o Custom Gene Synthesis
o Gene Library Synthesis
o By Length
o Less than 500 nt
o 501-1000 nt
o 1001-1500 nt
o 1501-2000 nt
o 2001-2500 nt
o More than 2500 nt
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Research and Development
o Oligonucleotide Synthesis
o PCR
o NGS
o CRISPR
o Cloning and Mutagenesis
o Others
o Gene Synthesis
o Synthetic Biology
o Vaccine Development
o Genetic Engineering
o Others
• Diagnostics
• Therapeutics
o RNAi Therapies
o Antisense Oligonucleotide-based Therapies
o Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical and Diagnostics Companies
• Academic and Research Institutes
• Contract Research Organizations

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service Type
1.2.2. Application
1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. U.S. DNA Synthesis Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. DNA synthesis Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
Chapter 4. U.S. DNA Synthesis Market: Service Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. DNA Synthesis Market Service Type Movement Analysis
4.3. U.S. DNA Synthesis Market Size & Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
4.4. Oligonucleotide synthesis
4.4.1. Oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. By Type
4.4.2.1. Standard oligonucleotides synthesis
4.4.2.1.1. Standard oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.2. Custom oligonucleotide synthesis
4.4.2.2.1. Custom oligonucleotides synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. By Length
4.4.3.1. Less than 50nt
4.4.3.1.1. Less than 50nt market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3.2. 51-100nt
4.4.3.2.1. 51-100nt market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3.3. 101-150nt
4.4.3.3.1. 101-150nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3.4. More than 150nt
4.4.3.4.1. More than 150nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Gene synthesis
4.5.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2. By Type
4.5.2.1. Custom gene synthesis
4.5.2.1.1. Custom gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2.2. Gene library synthesis
4.5.2.2.1. Gene library synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3. By Length
4.5.3.1. Less than 500nt
4.5.3.1.1. Less than 500nt market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.2. 501-1000nt
4.5.3.2.1. 501-1000nt market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.3. 1001-1500nt
4.5.3.3.1. 1001-1500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.4. 1501-2000nt
4.5.3.4.1. 1501-2000nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.5. 2001-2500nt
4.5.3.5.1. 2001-2500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3.6. More than 2500nt
4.5.3.6.1. More than 2500nt synthesis market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. DNA Synthesis Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. DNA Synthesis Market Application Movement Analysis
5.3. U.S. DNA Synthesis Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Research & Development
5.4.1. Research & development market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Oligonucleotide synthesis
5.4.2.1. Oligonucleotide synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.2. PCR
5.4.2.2.1. PCR synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.3. NGS
5.4.2.3.1. NGS synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.4. CRISPR
5.4.2.4.1. CRISPR synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.5. Cloning and mutagenesis
5.4.2.5.1. Cloning and mutagenesis synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2.6. Others
5.4.2.6.1. Others synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3. Gene synthesis
5.4.3.1. Gene synthesis market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3.2. Synthetic biology
5.4.3.2.1. Synthetic biology tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3.3. Vaccine development
5.4.3.3.1. Vaccine development synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3.4. Genetic engineering
5.4.3.4.1. Genetic engineering synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.4.3.5. Others
5.4.3.5.1. Others synthesis tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Diagnostics
5.5.1. Diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Therapeutics
5.6.1. Therapeutics market estimates and forecasts 2021 to 2033 (USD Million)
5.6.2. RNAi therapies
5.6.2.1. RNAi therapies market estimates and forecasts 2021 to 2033 (USD Million)
5.6.3. Antisense and oligonucleotide-based therapies
5.6.3.1. Antisense and oligonucleotide-based therapies market estimates and forecasts 2021 to 2033 (USD Million)
5.6.4. Others
5.6.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. DNA Synthesis Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. DNA Synthesis Market End Use Movement Analysis
6.3. U.S. DNA Synthesis Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Diagnostic Companies
6.4.1. Biopharmaceutical & diagnostic companies market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Contract Research Organizations
6.6.1. Contract Research Organizations market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Service benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Twist Bioscience
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Service benchmarking
7.4.2.4. Strategic initiatives
7.4.3. BIONEER CORPORATION
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Service benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Eton Bioscience, Inc
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Service benchmarking
7.4.4.4. Strategic initiatives
7.4.5. LGC Biosearch Technologies
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Service benchmarking
7.4.5.4. Strategic initiatives
7.4.6. IBA Lifesciences GmbH
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Service benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Eurofins Scientific
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Service benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Integrated DNA Technologies, Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Service benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Quintara Biosciences
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Service benchmarking
7.4.9.4. Strategic initiatives
7.4.10. GenScript
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Service benchmarking
7.4.10.4. Strategic initiatives